Loading...
Market
Story
Scholar Rock ($SRRK) Shares Soar 200% After Apitegromab Succeeds in Phase 3 SAPPHIRE SMA Study
Oct 7, 2024, 11:15 AM
Scholar Rock (NASDAQ: $SRRK) announced topline results showing that its drug apitegromab met the primary endpoint in the late-stage Phase 3 SAPPHIRE study for treating patients with spinal muscular atrophy (SMA). The study demonstrated a statistically significant and clinically meaningful improvement in motor function among participants. Patients enrolled in the trial had been on either Evrysdi or Spinraza, existing treatments for SMA. The primary endpoint was achieved with a p-value of 0.019, with the 10 mg dose showing superior results. Following the positive trial results, Scholar Rock's stock soared more than 200%.
View original story
Similar markets
Yes • 50%
No • 50%
Leader • 25%
Top 3 • 25%
Top 5 • 25%
Outside Top 5 • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
FDA approval • 25%
FDA rejection • 25%
Conditional approval • 25%
No decision • 25%
Yes • 50%
No • 50%
Less than $200 million • 25%
$200 million to $400 million • 25%
$400 million to $600 million • 25%
More than $600 million • 25%
Less than $500 million • 25%
$500 million - $1 billion • 25%
$1 billion - $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $2 billion • 25%
More than $2 billion • 25%